Alexander Edemskiy, Oksana Vasiltseva, Elena Kliver, Natalya Novikova, Dmitry Sirota, Alexander Chernyavskiy
{"title":"肺动脉血管肉瘤的外科治疗-十年经验。","authors":"Alexander Edemskiy, Oksana Vasiltseva, Elena Kliver, Natalya Novikova, Dmitry Sirota, Alexander Chernyavskiy","doi":"10.21470/1678-9741-2023-0441","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pulmonary artery angiosarcoma is a rare and extremely severe tumor. Our study summarizes the clinical data of patients treated for pulmonary artery angiosarcoma over the period of 2010-2020.</p><p><strong>Methods: </strong>We retrospectively analyzed cases of surgical treatment of patients with diagnosis of pulmonary artery angiosarcoma at our center. Data of operative findings, short-term follow-up, and the long-term results were reviewed where available.</p><p><strong>Results: </strong>The 30-day mortality rate was six (67%) out of nine patients. Three (33%) patients were discharged. Data on pulmonary vascular resistance in the earlyand long-term postoperative periods were assessed if possible. Certain computed tomography signs have been identified that can be used to suspect pulmonary artery angiosarcoma and make a differential diagnosis with chronic thromboembolic pulmonary hypertension.</p><p><strong>Conclusion: </strong>The surgical treatment of choice is pneumonectomy with contralateral pulmonary endarterectomy. Oncological vigilance regarding angiosarcoma in occlusive-stenotic lesions of the pulmonary artery is extremely important. Patients' assessment must be carried out in an expert cardiothoracic surgery center with the involvement of an oncological crew.</p>","PeriodicalId":72457,"journal":{"name":"Brazilian journal of cardiovascular surgery","volume":"40 4","pages":"e20230441"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175617/pdf/","citationCount":"0","resultStr":"{\"title\":\"Surgical Treatment of Pulmonary Artery Angiosarcoma - A Ten-Year Experience.\",\"authors\":\"Alexander Edemskiy, Oksana Vasiltseva, Elena Kliver, Natalya Novikova, Dmitry Sirota, Alexander Chernyavskiy\",\"doi\":\"10.21470/1678-9741-2023-0441\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Pulmonary artery angiosarcoma is a rare and extremely severe tumor. Our study summarizes the clinical data of patients treated for pulmonary artery angiosarcoma over the period of 2010-2020.</p><p><strong>Methods: </strong>We retrospectively analyzed cases of surgical treatment of patients with diagnosis of pulmonary artery angiosarcoma at our center. Data of operative findings, short-term follow-up, and the long-term results were reviewed where available.</p><p><strong>Results: </strong>The 30-day mortality rate was six (67%) out of nine patients. Three (33%) patients were discharged. Data on pulmonary vascular resistance in the earlyand long-term postoperative periods were assessed if possible. Certain computed tomography signs have been identified that can be used to suspect pulmonary artery angiosarcoma and make a differential diagnosis with chronic thromboembolic pulmonary hypertension.</p><p><strong>Conclusion: </strong>The surgical treatment of choice is pneumonectomy with contralateral pulmonary endarterectomy. Oncological vigilance regarding angiosarcoma in occlusive-stenotic lesions of the pulmonary artery is extremely important. Patients' assessment must be carried out in an expert cardiothoracic surgery center with the involvement of an oncological crew.</p>\",\"PeriodicalId\":72457,\"journal\":{\"name\":\"Brazilian journal of cardiovascular surgery\",\"volume\":\"40 4\",\"pages\":\"e20230441\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175617/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brazilian journal of cardiovascular surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21470/1678-9741-2023-0441\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brazilian journal of cardiovascular surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21470/1678-9741-2023-0441","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Surgical Treatment of Pulmonary Artery Angiosarcoma - A Ten-Year Experience.
Introduction: Pulmonary artery angiosarcoma is a rare and extremely severe tumor. Our study summarizes the clinical data of patients treated for pulmonary artery angiosarcoma over the period of 2010-2020.
Methods: We retrospectively analyzed cases of surgical treatment of patients with diagnosis of pulmonary artery angiosarcoma at our center. Data of operative findings, short-term follow-up, and the long-term results were reviewed where available.
Results: The 30-day mortality rate was six (67%) out of nine patients. Three (33%) patients were discharged. Data on pulmonary vascular resistance in the earlyand long-term postoperative periods were assessed if possible. Certain computed tomography signs have been identified that can be used to suspect pulmonary artery angiosarcoma and make a differential diagnosis with chronic thromboembolic pulmonary hypertension.
Conclusion: The surgical treatment of choice is pneumonectomy with contralateral pulmonary endarterectomy. Oncological vigilance regarding angiosarcoma in occlusive-stenotic lesions of the pulmonary artery is extremely important. Patients' assessment must be carried out in an expert cardiothoracic surgery center with the involvement of an oncological crew.